These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25812544)

  • 21. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
    Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
    J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Priapism Associated With Atypical Antipsychotic Medications: A Clinical Report.
    Ferreira LP; Ferreira TF; Godinho FF; Tomé MC; Vieira CJ; Luís AR; Maia T
    Prim Care Companion CNS Disord; 2020 Jul; 22(4):. PubMed ID: 32678522
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute agranulocytosis when switching from risperidone to paliperidone.
    Wakuda T; Suzuki A; Hasegawa M; Ichikawa D; Yamasue H
    Aust N Z J Psychiatry; 2019 Jun; 53(6):586-587. PubMed ID: 30636434
    [No Abstract]   [Full Text] [Related]  

  • 24. Postinjection Delirium/Sedation Syndrome After Paliperidone Palmitate Injection in a Bipolar Affective Disorder Patient: A Case Report.
    Olguner Eker Ö; Turan T; Sarilar AC; Danaci Sezgin Sİ
    J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):319-321. PubMed ID: 38656231
    [No Abstract]   [Full Text] [Related]  

  • 25. Paliperidone-Associated Hyponatremia: Report of a Fatal Case With Analysis of Cases Reported in the Literature and to the US Food and Drug Administration Adverse Event Reporting System.
    Mazhar F; Carnovale C; Haider N; Ahmed R; Taha M
    J Clin Psychopharmacol; 2020; 40(2):202-205. PubMed ID: 32068565
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of the overdose of paliperidone 3-monthly injection: A case report.
    Jin FX; Malik A
    Australas Psychiatry; 2023 Jun; 31(3):405-406. PubMed ID: 36913290
    [No Abstract]   [Full Text] [Related]  

  • 28. Bromocriptine mitigated paliperidone metabolic and neuro-hormonal side effects and improved negative domain in a case of early onset schizophrenia.
    Naguy A; Al-Tajali A
    Nord J Psychiatry; 2016; 70(4):318-9. PubMed ID: 26573387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two long-acting injectable antipsychotics for schizophrenia.
    Med Lett Drugs Ther; 2015 Nov; 57(1481):152-3. PubMed ID: 26529133
    [No Abstract]   [Full Text] [Related]  

  • 31. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia.
    Alphs L; Mao L; Lynn Starr H; Benson C
    Schizophr Res; 2016 Feb; 170(2-3):259-64. PubMed ID: 26742509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed-onset of psychopharmacologically induced priapism: A cautionary case report.
    Birur B; Fargason RE; Moore N
    Asian J Psychiatr; 2015 Oct; 17():106. PubMed ID: 26188724
    [No Abstract]   [Full Text] [Related]  

  • 33. Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: a case series analysis.
    Star K; Iessa N; Almandil NB; Wilton L; Curran S; Edwards IR; Wong IC
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):440-51. PubMed ID: 23234587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paliperidone-induced tardive dystonia: a case report.
    Havaki-Kontaxaki B; Karaiskos D; Pappa D; Papadimitriou GN
    J Neuropsychiatry Clin Neurosci; 2013; 25(2):E51. PubMed ID: 23686064
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness of long-acting paliperidone palmitate in borderline personality disorder.
    Palomares N; Montes A; Díaz-Marsá M; Carrasco JL
    Int Clin Psychopharmacol; 2015 Nov; 30(6):338-41. PubMed ID: 26230268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
    Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tardive dyskinesia induced by a switch from haloperidol depot to paliperidone palmitate.
    Hsu CY; Lin YH; Shen YC
    J Neuropsychiatry Clin Neurosci; 2013; 25(4):E46-7. PubMed ID: 24247889
    [No Abstract]   [Full Text] [Related]  

  • 38. Possible paliperidone-induced neuroleptic malignant syndrome: a case report.
    Özdemir A; Aksoy-Poyraz C; Kılıç-Yener E
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):E22-3. PubMed ID: 23037666
    [No Abstract]   [Full Text] [Related]  

  • 39. Comment on: low-dose quetiapine-induced severe rhabdomyolysis.
    Ceri M; Unverdi S; Altay M; Duranay M
    Ren Fail; 2011; 33(4):463-4. PubMed ID: 21529278
    [No Abstract]   [Full Text] [Related]  

  • 40. [Rhabdomyolysis with antipsychotic drug treatment: a case report].
    Boulicot V; Merlot A; Sebeyran A; Viala A; Vacheron MN
    Therapie; 2012; 67(5):484-7. PubMed ID: 23241261
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.